Vxus stock price forecast aligns with improving dividend yields

VXUS stock price forecast aligns with improving dividend yields abroad, attracting income-focused investors. Yield stability around 2.6% supports price appreciation alongside fundamental gains. Novo Nordisk A/S (NYSE:NVO) is the top holding of Vanguard FTSE Developed Markets Index Fund ETF Shares (NYSE:VEA). The company is involved in the research, development, manufacture, and distribution of pharmaceutical products globally. On January 31, Novo Nordisk A/S (NYSE:NVO) reported a Q4 GAAP EPS of DKK 4.91 and a revenue of DKK 65.86 billion, up 37% on a year-over-year basis. This Vanguard ETF is a good option because it provides income regardless of its stock price performance. Obviously, it's good to have both stock price appreciation and a solid dividend, but the former is never guaranteed, while the latter is. To further maximize this fund's benefits, consider reinvesting dividends to acquire more shares instead of receiving cash payouts. Institutional traders monitor VXUS stock price forecast closely due to its diversified exposure. Strength in Japanese equities combined with resilience in developed European markets supports a one-month price target of $59.85.